Key Takeaways: How Regulatory Exclusivity, PTA, PTE, and Double Patenting Shape Pharmaceutical Lifecycle Value

Pharmaceutical lifecycle value is often at its highest towards the end of the patent term. With longer development timelines and potential patent challenges, life sciences companies must understand how FDA regulatory exclusivities, patent term adjustment (PTA), patent term extension (PTE), and obviousness-type double patenting (ODP) interact. Relatively small timing differences can significantly affect competitive entry and business outcomes.

During our recent webinar, Counting the Days—How Regulatory Exclusivity, PTE, PTA, and ODP Coalesce to Influence Lifecycle, Sterne Kessler Directors Deborah Sterling, Ph.D., John Covert, and Dennies Varughese highlighted several practical insights for companies developing a lifecycle strategy for their products.

1. Regulatory Exclusivity Can Operate as a Standalone Barrier: FDA exclusivities may delay competition even if patents expire earlier or are successfully challenged, providing meaningful independent protection.
2. PTA Extends Term but May Introduce Risk: While PTA can add valuable time to a patent’s life, disproportionate PTA across related patents can increase exposure to double patenting challenges.
3. PTE Selection Is a Strategic Choice: Choosing which patent to extend requires balancing term length against claim scope, enforceability, and vulnerability to invalidity or ODP attacks.
4. ODP Analysis Is Increasingly Fact-Specific: Recent decisions emphasize filing sequence and family structure, underscoring the importance of evaluating ODP risk across entire portfolios.
5. Holistic Planning Preserves Value: Aligning regulatory exclusivities, patent strategy, and litigation planning enhances predictability and helps preserve value through loss of exclusivity.

Maximizing exclusivity requires coordinated planning across regulatory, prosecution, and enforcement teams. By treating regulatory exclusivities, PTA, PTE, and ODP as interconnected tools, companies can better protect innovation, anticipate loss-of-exclusivity timing, and support sound commercial decision-making. Ongoing monitoring and early strategic alignment remain essential as this area of law continues to evolve. Watch the on demand webinar for further analysis.